Affiliation:
1. Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University
Hospital, Seville, Spain
2. Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/
University of Seville, Seville, Spain
3. Department of Molecular Biology and Biochemical Engineering,
Andalusian Center of Developmental Biology, CSIC, University of Pablo de Olavide, Seville, Spain
Abstract
:
Bacterial infections are among the leading causes of death worldwide. The
emergence of antimicrobial resistance factors threatens the efficacy of all current antimicrobial
agents, with some already made ineffective, and, as a result, there is an urgent
need for new treatment approaches. International organizations, such as the World
Health Organization and the European Centre for Diseases Control, have recognized infections
caused by multi-drug-resistant (MDR) bacteria as a priority for global health action.
:
Classical antimicrobial drug discovery involves in vitro screening for antimicrobial candidates,
Structure-Activity Relationship analysis, followed by in vivo testing for toxicity.
Bringing drugs from the bench to the bedside involves huge expenditures in time and resources.
This, along with the relatively short window of therapeutic application for antibiotics
attributed to the rapid emergence of drug resistance, has, at least until recently, resulted
in a waning interest in antibiotic discovery among pharmaceutical companies. In
this environment, “repurposing” (defined as investigating new uses for existing approved
drugs) has gained renewed interest, as reflected by several recent studies, and may help
to speed up the drug development process and save years of expensive research invested
in antimicrobial drug development.
:
The goal of this review is to provide an overview of the scientific evidence on potential
anthelmintic drugs targeting Gram-negative bacilli (GNB). In particular, we aim to: (i)
highlight the potential of anthelmintic drugs for treatments of GNB infections, (ii) review
their mechanisms of action against these bacteria, (iii) summarize the outcome of preclinical
studies investigating approved anthelmintic drugs that target these bacteria, (iv) provide
critical challenges for further anthelmintic repurposing drugs development, and (v)
list the specific anthelmintic drugs that may be more likely to be repurposed.
Funder
Instituto de Salud Carlos III, Proyectos de Investigación en Salud
Ministerio de Economía y Competitividad of Spain
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献